Therapeutic interventions aiming at early AD stages (e.g., presence of Aβ pathology but lack of over tau pathology) would include biofluid-based stage-1 participants (p-tau217 positive), whereas an intervention focusing on individuals with Aβ pathology and initial signs of tau pathology would include biofluid-based stage-2 cases (p-tau217 and p-tau205 positive, NTA-tau negative). Here, MAPT is linked to Alzheimer disease.